CD19 Antibody

What is CD19 and why is it a significant target for antibody-based research?

CD19 is a B-lymphocyte surface antigen that functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. It is also known by alternative names including B4, CVID3, B-lymphocyte antigen CD19, and B-lymphocyte surface antigen B4 . The protein has a molecular weight of approximately 61.1 kilodaltons .

CD19 plays a critical role in B cell activation, differentiation, and survival by:

• Decreasing the threshold for activation of downstream signaling pathways

• Triggering B-cell responses to antigens

• Activating signaling pathways that lead to phosphatidylinositol 3-kinase activation

• Mobilizing intracellular calcium stores

This protein is significant for antibody research because it serves as a reliable marker for B cells and is expressed throughout B-cell development, making it valuable for both diagnostic applications and therapeutic targeting. Its involvement in multiple B-cell malignancies and autoimmune conditions further enhances its research importance .

What detection methods are commonly used for CD19 antibodies in research settings?

CD19 antibodies are employed in multiple detection methods, with the most common being:

• Flow Cytometry (FC): A high-throughput technique that allows simultaneous measurement of multiple parameters in the same sample. Flow cytometry can quantitatively measure CD19 expression levels on cell surfaces, providing information about both the percentage of CD19-positive cells and the relative abundance of CD19 molecules per cell .

• Immunohistochemistry (IHC): Used for detecting CD19 in formalin-fixed paraffin-embedded (FFPE) tissue samples. This technique provides spatial information about CD19 expression within tissue architecture, though it is generally less quantitative than flow cytometry .

• Western Blotting (WB): Used to confirm the presence and molecular weight of CD19 protein in cell or tissue lysates .

• Immunocytochemistry/Immunofluorescence (ICC/IF): Allows visualization of CD19 localization within cells .

• Mass Cytometry (CyTOF): An advanced technique that combines flow cytometry with mass spectrometry, allowing for more parameters to be measured simultaneously with reduced spillover between channels .

Each method has specific applications, advantages, and limitations that researchers must consider based on their experimental objectives.

How can I validate the specificity of my CD19 antibody?

Validating antibody specificity is crucial for reliable experimental results. For CD19 antibodies, consider these validation approaches:

• Positive and Negative Controls:

  • Use cell lines known to express CD19 (e.g., Raji, MEC-1, JVM-2) as positive controls

  • Use CD19-negative cell lines as negative controls

  • Consider using B cell-depleted samples as additional negative controls

• Multiple Detection Methods:

  • Confirm results using different techniques (e.g., flow cytometry and immunohistochemistry)

  • Different methods may provide complementary information about antibody specificity

• Antibody Competition Assays:

  • Test whether your antibody competes with other well-characterized anti-CD19 antibodies

  • Competition indicates binding to the same or overlapping epitopes

• Genetic Approaches:

  • Use CD19 knockout cells or tissues

  • Employ CD19 overexpression systems to confirm specificity

• Epitope Mapping:

  • Determine which region of CD19 your antibody recognizes (intracellular vs. extracellular domain)

  • This information helps interpret results and predict potential cross-reactivity

When selecting validation methods, consider the specific application (FC, IHC, WB, etc.) as validation requirements may differ between techniques.

How do I address CD19 epitope masking in samples from patients treated with anti-CD19 therapies?

Epitope masking is a significant concern when analyzing CD19 expression in samples from patients who have received anti-CD19 therapeutics such as tafasitamab. This phenomenon can lead to false negative results and misinterpretation of CD19 expression status. Research has identified several key approaches to address this challenge:

• Acidic Dissociation Protocol:

  • An acidic dissociation buffer (e.g., D-PBS + 3% FCS, pH 2.1 adjusted with HCl) can remove pre-bound therapeutic antibodies from CD19 on the cell surface

  • The protocol typically involves:

    • Resuspending cells in acidic buffer

    • Neutralizing with excess FACS buffer

    • Repeating the procedure multiple times before staining

• Selection of Non-Competing Detection Antibodies:

  • For immunohistochemistry (IHC), antibody clones that bind to non-overlapping epitopes can be used

  • IHC antibodies targeting the intracellular domain of CD19 avoid competition with therapeutics that target the extracellular domain

• Dual Analysis Approach:

  • Perform detection both with and without acidic dissociation

  • This provides information about both CD19 occupancy by the therapeutic and total CD19 expression levels

Research has shown that while CD19 could be successfully detected on tafasitamab pre-treated samples using various IHC antibody clones, flow cytometry detection required acidic dissociation to avoid false negative results due to epitope masking .

What are the considerations for quantitative assessment of CD19 expression?

Accurate quantitative assessment of CD19 expression is critical for diagnostic applications and therapeutic monitoring. Several methodological considerations should be addressed:

• Flow Cytometry Quantification:

  • Antibodies Bound Per Cell (ABC): This approach provides an absolute measure of CD19 molecules on cell surfaces

  • Calibration Methods: Two primary approaches include:

    • Single-point calibration using reference cells (e.g., CD4 reference cells)

    • Bead-based calibration (e.g., QuantiBrite PE beads)

• Mass Cytometry (CyTOF) Quantification:

  • Allows multi-parameter analysis with less signal overlap than traditional flow cytometry

  • Calibration methods include EQ4 and bead-based approaches

• Variables Affecting Quantification:

  • Antibody clone and fluorochrome selection

  • Instrument setup and calibration

  • Sample preparation protocols

  • Operator variability

  • Experimental day-to-day variation

• Limitations of IHC for Quantification:

  • IHC generally provides qualitative rather than quantitative assessment

  • Cannot reliably discriminate between different levels of CD19 expression

  • Staining intensity can be affected by chromogen incubation duration

• Reference Materials:

  • Well-characterized biological reference materials are essential for standardizing assays

  • Commercial PBMCs from different manufacturers may have variable CD19 expression levels

Researchers should select quantification methods appropriate for their specific research questions and consider including appropriate controls and reference materials to ensure reliable and reproducible measurements.

How do CD19 antibody affinity and epitope influence their research applications?

The affinity and epitope specificity of CD19 antibodies significantly impact their research applications and performance in various experimental contexts:

• Affinity Considerations:

  • High-affinity antibodies (picomolar range) with slow off-rates may be preferable for detecting low-expressing CD19+ cells

  • For therapeutic applications, affinity can be "tuned" to optimize specific outcomes (e.g., CLN-978 uses picomolar affinity for CD19 targeting)

  • Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI) can be used to determine antibody affinities for CD19

• Epitope Targeting:

  • Extracellular Domain: Antibodies targeting the extracellular domain are suitable for:

    • Flow cytometry on live cells

    • Therapeutic applications

    • These may compete with therapeutic antibodies like tafasitamab

  • Intracellular Domain: Antibodies targeting the intracellular domain are suitable for:

    • Immunohistochemistry on fixed tissues

    • Detection in samples from patients who received anti-CD19 therapeutics

    • These avoid competition with therapeutics targeting extracellular domains

• Cross-Reactivity:

  • Human CD19 antibodies may cross-react with orthologs from other species (canine, porcine, monkey, mouse, rat)

  • Species cross-reactivity should be validated experimentally for each application

  • Cross-reactivity is particularly important for preclinical studies in animal models

• Application-Specific Selection:

  • For flow cytometry: Consider fluorochrome brightness, potential for spectral overlap

  • For IHC: Consider antibody performance in fixed tissues and compatibility with detection systems

  • For therapeutic development: Consider half-life, biodistribution, and functional effects

Understanding the relationship between antibody properties and intended applications is crucial for selecting the most appropriate CD19 antibodies for specific research questions.

What are the best practices for analyzing CD19 expression by flow cytometry?

Flow cytometry is a primary method for CD19 detection in research settings. Following best practices ensures reliable and reproducible results:

• Sample Preparation:

  • Process samples promptly or use appropriate preservatives

  • Use consistent protocols for cell isolation and preparation

  • Include viability dyes to exclude dead cells from analysis

  • Consider using Fc receptor blocking reagents to reduce non-specific binding

• Antibody Selection and Titration:

  • Choose antibody clones validated for flow cytometry

  • Be aware that some clones (e.g., OTI3B10) may not bind to all CD19+ cell lines equally

  • Perform antibody titration to determine optimal concentration

  • Consider fluorochrome brightness based on expected CD19 expression levels

• Control Samples:

  • Include positive controls (e.g., Raji cells for high CD19 expression, JVM-2 for low expression)

  • Include negative controls (CD19-negative cell lines)

  • Use isotype controls or fluorescence-minus-one (FMO) controls

• Instrument Setup and Calibration:

  • Use standardized instrument settings

  • Include calibration beads for fluorescence quantification

  • Consider using CD19 reference materials for assay standardization

• Special Considerations for Treated Samples:

  • For samples from patients treated with anti-CD19 therapeutics, use acidic dissociation protocols to remove bound therapeutic antibodies

  • Consider analyzing samples both with and without acidic dissociation to assess both occupancy and total CD19 expression

• Data Analysis:

  • Use consistent gating strategies

  • Consider quantitative approaches (antibodies bound per cell, ABC)

  • Account for variables such as operator, instrument, and day-to-day variation

Following these practices enhances the reliability and reproducibility of CD19 expression analysis by flow cytometry.

How can I establish reliable CD19 reference materials for assay standardization?

Establishing reliable reference materials is crucial for standardizing CD19 detection assays across experiments, instruments, and laboratories:

• Selection of Biological Reference Materials:

  • Commercial PBMCs from healthy donors can serve as reference materials

  • Cell lines with stable CD19 expression (e.g., Raji for high expression, JVM-2 for low expression)

  • Consider creating fixed cell preparations for long-term stability

• Characterization of Reference Materials:

  • Quantify CD19 expression using multiple methods:

    • Flow cytometry with quantitative beads

    • Mass cytometry (CyTOF)

    • Molecular quantification methods

  • Assess stability over time under various storage conditions

  • Evaluate lot-to-lot consistency for commercial materials

• Variables to Control and Document:

  • PBMCs manufacturing process

  • Number of donors used in each lot

  • Antibody reagent specifics (clone, lot, concentration)

  • Operator variability

  • Day-to-day experimental variation

• Calibration Methods:

  • Single-point calibration using well-characterized reference cells

  • Bead-based calibration using standardized beads (e.g., QuantiBrite PE)

  • Mass cytometry calibration using EQ4 or bead-based approaches

• Documentation and Distribution:

  • Document detailed protocols for reference material use

  • Establish consensus values for CD19 expression levels

  • Consider multicenter validation studies

  • Develop standard operating procedures (SOPs)

By establishing and properly characterizing CD19 reference materials, researchers can improve the comparability of results between experiments and laboratories, enhancing the reliability and reproducibility of CD19-related research.

What controls should be included in CD19 antibody experiments for different applications?

Appropriate controls are essential for ensuring reliable and interpretable results in CD19 antibody experiments across different applications:

Table 1: Recommended Controls for CD19 Antibody Experiments by Application

Beyond these basic controls, consider the following application-specific recommendations:

• Flow Cytometry Additional Controls:

  • CD19 expression range controls (high, medium, low expressing cells)

  • Compensation controls for multicolor panels

  • Instrument setup and calibration controls

  • Antibody titration controls to determine optimal concentration

• Immunohistochemistry Additional Controls:

  • Controls for different fixation conditions

  • Chromogen incubation time controls (affects staining intensity)

  • Controls for both intracellular and extracellular CD19 epitopes

• Quantitative Studies Additional Controls:

  • Reference cells with known CD19 levels

  • Calibration beads for quantitative fluorescence

  • Inter-assay reproducibility controls

• Therapeutic Monitoring Additional Controls:

  • Pre-treatment samples from the same source

  • Controls treated with relevant therapeutic antibodies

  • Epitope competition controls

Incorporating these controls helps identify potential technical issues, validates results, and enables proper interpretation of experimental findings across different CD19 antibody applications.

How do I troubleshoot weak or absent CD19 staining in my experiments?

Weak or absent CD19 staining can result from multiple factors. This troubleshooting guide addresses common issues and their solutions:

• Technical Issues:

  • Antibody Degradation: Verify antibody storage conditions and expiration date

  • Insufficient Antibody Concentration: Perform antibody titration to determine optimal concentration

  • Sample Degradation: Ensure proper sample handling and storage

  • Steric Hindrance: Consider different antibody clones targeting different epitopes

• Biological Factors:

  • Low CD19 Expression: Some cell types (e.g., JVM-2) naturally express lower CD19 levels than others (e.g., Raji)

  • CD19 Downregulation: B cells may downregulate CD19 in certain activation states or disease conditions

  • B Cell Depletion: Samples may have reduced B cell numbers due to therapy or disease

• Epitope Masking:

  • If samples are from patients treated with anti-CD19 therapies (e.g., tafasitamab), therapeutic antibodies may block detection epitopes

  • Solution: Implement acidic dissociation protocols to remove bound therapeutic antibodies before staining

  • Protocol: Resuspend cells in acidic buffer (D-PBS + 3% FCS, pH 2.1), neutralize with excess FACS buffer, repeat 3 times

• Method-Specific Issues:

  • Flow Cytometry: Check compensation settings, detector voltage, and fluorochrome selection

  • IHC: Verify antigen retrieval methods, consider different fixation protocols, optimize chromogen development time

  • Western Blotting: Check lysis conditions, protein transfer efficiency, and blocking protocols

• Clone-Specific Considerations:

  • Some antibody clones may not work effectively with certain cell types

  • Example: Clone OTI3B10 works for Raji cells but not MEC-1 or JVM-2 in flow cytometry

  • Test multiple validated antibody clones for your specific application and cell type

When troubleshooting, implement changes systematically and include appropriate controls to identify the source of the problem and validate the solution.

What considerations are important when developing or selecting CD19-targeted therapeutics?

Development and selection of CD19-targeted therapeutics involves several key considerations that researchers should address:

• CD19 Expression Heterogeneity:

  • Target cell populations may have variable CD19 expression levels

  • Therapeutics may need to effectively target both high and low CD19-expressing cells

  • Consider affinity-tuned approaches for optimal targeting across expression levels

• Antibody Engineering Considerations:

  • Affinity Optimization:

    • Picomolar affinity antibodies with slow off-rates may be optimal for targeting low CD19-expressing cells

    • Example: CLN-978 uses an affinity-matured scFv with picomolar affinity for CD19

  • Format Selection:

    • Various formats are available (full antibodies, scFvs, single-domain antibodies)

    • Format affects tissue penetration, half-life, and effector functions

    • Multispecific formats can engage multiple targets (e.g., CD19/CD3 bispecifics)

• Pharmacokinetic Optimization:

  • Half-life Extension Strategies:

    • Incorporation of serum albumin binding domains

    • Fc engineering for enhanced FcRn binding

    • Example: CLN-978 includes a humanized anti-serum albumin single-domain antibody (sdAb) for half-life extension

• Species Cross-Reactivity:

  • Important for preclinical safety assessment

  • Cynomolgus monkey cross-reactivity is often evaluated

  • Consider potential differences in epitope structure across species

• Post-Treatment Monitoring:

  • Strategies for detecting CD19 expression after therapeutic administration

  • Methods to distinguish between CD19 downregulation and epitope masking

  • Consideration of treatment sequencing with other CD19-targeted therapies

• Resistance Mechanisms:

  • CD19 loss has been reported after some therapies (e.g., CART19)

  • Monitoring strategies for CD19 expression are crucial for guiding subsequent therapy decisions

Researchers developing or selecting CD19-targeted therapeutics should carefully consider these factors to optimize therapeutic efficacy and enable proper monitoring of treatment responses.